🇺🇸 FDA
Pipeline program

Vidaza 25 mg/ml powder for suspension for injection, Azacitidin STADA 25 mg/ml Pulver zur Herstellung einer Injektionssuspension, Venclyxto 10 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, Azacitidine Mylan 25 mg/mL powder for suspension for injection, Azacitidine Mylan 25 mg/mL powder for suspension for injection, pevonedistat hydrochloride, Venclyxto 100 mg film-coated tablets

Pevonedistat-2002

Phase 2 small_molecule active

Quick answer

Vidaza 25 mg/ml powder for suspension for injection, Azacitidin STADA 25 mg/ml Pulver zur Herstellung einer Injektionssuspension, Venclyxto 10 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, Azacitidine Mylan 25 mg/mL powder for suspension for injection, Azacitidine Mylan 25 mg/mL powder for suspension for injection, pevonedistat hydrochloride, Venclyxto 100 mg film-coated tablets for Acute Myeloid Leukemia is a Phase 2 program (small_molecule) at Takeda Pharmaceuticals International AG with 1 ClinicalTrials.gov record(s).

Program details

Company
Takeda Pharmaceuticals International AG
Indication
Acute Myeloid Leukemia
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials